Member news

FUJIFILM Biotechnologies celebrated the grand opening of its expanded site in Teesside, UK, today.

Microbiotica announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.

Coulter Partners successfully led a search assignment for Concept Life Sciences and is pleased to announce the placement of Dr. Adam Davenport as Chief Scientific Officer (CSO).

To mark National Apprenticeship Week (9 - 15 February), Kent’s science and technology hub Discovery Park is calling for more young people to consider higher apprenticeships as a route into rewarding careers in STEM (Science, Technology, Engineering, and Maths).

PIR International recently partnered with Maxion Therapeutics in appointing Helen Timmis as VP of Clinical Development.

Bidwells has completed the merger of Creative Places LLP into the firm, strengthening its Science & Technology capability and further enhancing its expertise in R&D and innovation-led real estate.

ARC has launched Motherlabs Oxford, a new purpose-built life sciences accelerator space at its ARC Oxford campus, expanding its early-stage laboratory offering in response to sustained demand across the sector.

Brainomix is set to launch its new Brainomix 360 Next Generation platform at the International Stroke Conference (ISC).

Coulter Partners successfully led a search assignment for Kaffe Bueno and is pleased to announce the placement of Thomas Durhuus as Chief Executive Officer (CEO).

Fleet Bioprocessing Ltd has announced the launch of a new contract development service for Lateral Flow Devices (LFDs), expanding its capabilities in response to strong growth in point-of-care and decentralised diagnostics.

Complement Therapeutics GmbH (CTx) has received Clinical Trial Authorisation (CTA) approval in the United Kingdom for CTx001.

Collaboration to Deliver High-Quality Cytokines and Growth Factors to Enable the Advancement of Stem Cell-Based Therapeutics

Poolbeg Pharma (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology.

PIR International recently partnered with Dynamic42 in appointing Wolfgang Kintzel as Executive Chair

Professor Cathy Tralau-Stewart, Executive Director of the Milner Therapeutics Institute, has continued her thought leadership work with an article in Drug Discovery World.

Scancell Holdings plc, the developer of active immunotherapies to treat cancer, announces the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a registrational Phase 3 trial of its iSCIB1+ Immunobody® in advanced melanoma, with progression free survival as the agreed surrogate endpoint.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for TreeFrog Therapeutics and is pleased to announce the placement of Mark Rothera as Chief Executive Officer (CEO).

Stablepharma will apply its proprietary stabilisation technology, initially focused on vaccines, to non-vaccine sterile injectables that currently require cold-chain storage. Stablepharma will be eligible to receive future milestone and royalty revenue from AFT upon commercialisation.

The Cell and Gene Therapy Catapult (CGT Catapult) has published new insights into the UK’s CGT clinical trials in its 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.

Infinitopes announced its second close of its seed financing round, securing an additional $15.4 million and bringing the total raised to $35.1 million.